MSLN

A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Retrieved on: 
Mercredi, mai 29, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, HLA, Patient, Toxicity, Mayo Clinic, Clinical trial, Allele, FIH, LOH, Safety, Leukapheresis, Carcinoembryonic antigen, ASCO, Medicine, Society, MSLN, CEA, Annual general meeting, Pharmaceutical industry

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, will present updates on three ongoing clinical trials in poster presentations during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, will present updates on three ongoing clinical trials in poster presentations during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • “Diversity in clinical studies is essential to address racial and ethnic groups who are often underrepresented in clinical trials, especially in precision medicine studies using genetic data.
  • We are creating the future of precision medicine by applying advanced bioinformatics in our BASECAMP-1 prescreening protocol to efficiently screen patients for enrollment in these ongoing CAR T-cell clinical trials.
  • For more information on A2 Bio clinical trials, please visit https://www.a2bioclinicaltrials.com/

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024

Retrieved on: 
Mercredi, avril 10, 2024
PSMA, Institute of Cancer Research, Cancer, MSLN, Clinical Cancer Research, Cancer research, Research, The Institute, Half-life, PD-L1, Prostate cancer, CD137, VH, Therapy, Patient, APC, Toxicity, AACR, Antibody, Annual general meeting, Dynamics (music), Pharmacology, NK

Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer.

Key Points: 
  • Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer.
  • The data from our two lead programmes highlight the potential of immuno-oncology therapies that are potent and long-lasting, yet well-tolerated by patients.
  • “The pharmacology data we have shared on CB307, underpins its clinical development in PSMA+ metastatic castration-resistant prostate cancer (mCRPC), which continues at pace in our ongoing Phase 1b trial.
  • The details of this research have also been published in Clinical Cancer Research, a journal of the AACR.

A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Mercredi, avril 24, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CEA, ASCO, LOH, HLA, Carcinoembryonic antigen, MSLN, Patient, Society, Vaccine

A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the acceptance of three posters for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31-June 4, 2024, in Chicago, Ill. A2 Bio will present two Trials in Progress on its first-in-human Phase 1/2 studies EVEREST-1 and EVEREST-2, and one poster highlighting the BASECAMP-1 master prescreening study protocol’s impact on increasing trial diversity.

Key Points: 
  • A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the acceptance of three posters for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31-June 4, 2024, in Chicago, Ill. A2 Bio will present two Trials in Progress on its first-in-human Phase 1/2 studies EVEREST-1 and EVEREST-2, and one poster highlighting the BASECAMP-1 master prescreening study protocol’s impact on increasing trial diversity.
  • EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH)
    EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH)
    Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH)

Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting

Retrieved on: 
Jeudi, avril 4, 2024
Cell, MSLN, Synthetic biology, Doctor of Philosophy, IND, AACR, Lentivirus, Safety, OP1, Poster, NK

“T cell therapies have so far demonstrated modest efficacy against solid tumors, limited in part by poor expansion and functional persistence,” said Outpace CSO Aaron Foster, PhD .

Key Points: 
  • “T cell therapies have so far demonstrated modest efficacy against solid tumors, limited in part by poor expansion and functional persistence,” said Outpace CSO Aaron Foster, PhD .
  • “Our lead program OPB-101 incorporates multiple Outpace technologies that together drive durable responses in stringent preclinical models at very low treatment doses.
  • These attributes could potentially address the key barriers to efficacy and safety observed in previous solid tumor clinical studies.”
    Details of the poster presentations during the AACR annual meeting are below.
  • OPB-101 is the company’s lead pipeline program and is on track for an IND submission in Q4 2024.

Arsenal Biosciences Announces Presentation of Four Abstracts at AACR Annual Meeting Highlighting New CAR T-Focused Research

Retrieved on: 
Vendredi, avril 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Ovarian cancer, Short interspersed nuclear element, B cell, Fas, SPA, Glomus tumor, MSLN, Neoplasm, Research, RNA, Tumor microenvironment, Abstract, AACR, CA9, Clinical trial, Cancer, CRISPR, Primer, TCR, Engineering, PSMA, Cas9, ICT, Vaccine

Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.

Key Points: 
  • Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.
  • AB-2100 will be studied in a phase 1/2 clinical trial as a potential therapy for clear cell renal cell carcinoma (ccRCC) ( NCT06245915 ).
  • To better characterize CAR induction and receptor turnover, we conducted a series of assays, ultimately demonstrating preclinically that all PrimeR ICT cells have the potential to induce CAR.
  • Leveraging a reductionist in vitro model system, we were also able to analyze CAR induction and receptor turnover.

Harbour BioMed Reports Full Year 2023 Financial Results

Retrieved on: 
Jeudi, mars 28, 2024
GMG, Patient, Stock exchange, Quality of life, Protein engineering, Bank statement, Investment, Therapy, Research, HBM, Biotechnology, Partnership, ITM, Motherboard, Trial of the century, Neonatal Fc receptor, Safety, PD-L1, ADC, Hepatocellular carcinoma, Boston Children's Hospital, U.S. FDA, Longevity, MSLN, Harbor, Hospital, NK, Engineering, NMPA, AstraZeneca, Biology, Ecosystem, Idea, Pharmaceutical industry

We recorded a significant increase in our revenue, demonstrating the Company's excellent global business development capabilities," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.

Key Points: 
  • We recorded a significant increase in our revenue, demonstrating the Company's excellent global business development capabilities," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
  • Harbour BioMed recorded the profit of US$22.8 million for the year ended 31 December 2023.
  • This is the first time that the Company has recorded a net profit on its annual financial statements.
  • Looking to the future, Harbour BioMed will keep driving business growth and accomplishing its mission through two key pillars, Harbour Therapeutics and Nona Biosciences.

RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

Retrieved on: 
Vendredi, janvier 12, 2024
MMAE, Woman, FTD, Patient, European, ADC, Tissue, MSLN, Food, Disease, Safety, FDA, EOC, Ovarian cancer

This marks another significant development following the FDA's approval to RC88's international multicenter Phase II clinical trials last month.

Key Points: 
  • This marks another significant development following the FDA's approval to RC88's international multicenter Phase II clinical trials last month.
  • RC88 consists of a recombinant humanized anti-MSLN monoclonal antibody linked to the microtubule inhibitor monomethyl auristatin E (MMAE), which acts as a microtubule inhibitor.
  • The later the stage and the more aggressive the ovarian cancer, the higher the expression rate of MSLN, and current treatment options are limited.
  • Moving forward, RemeGen will continue to accelerate the development of its ADC products, with the aim of bringing more and better solutions to patients globally."

Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

Retrieved on: 
Jeudi, décembre 14, 2023
Harbor, IND, ADC, Pfizer, Therapy, MSLN, Partnership, Cancer, Ecosystem, ITM, Sales, Pharmaceutical industry

Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge technology innovation to novel therapeutics development.

Key Points: 
  • Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge technology innovation to novel therapeutics development.
  • Nona Biosciences is also eligible to receive tiered royalties on net sales ranging from high single digits to high teens.
  • "We are delighted to collaborate with Pfizer, a company that is committed to developing high-impact medicines for people living with cancer," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences.
  • This partnership with Pfizer further enhances Nona's global network of collaborations through innovative models, thereby amplifying the scientific and commercial value of our technology platforms."

A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Jeudi, novembre 2, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Tempus, Neoplasm, Patient, CAR, Society for Immunotherapy of Cancer, MSLN, Carcinoembryonic antigen, Cell, NYU, SITC, Immunotherapy, Lung, NGS, CEA, Medicine, AWARE, Annual general meeting, Mesothelioma, HLA, Pharmaceutical industry, Medical imaging, Vaccine, A2

Additionally, A2 Bio is presenting two posters on November 4, 2023, detailing the BASECAMP-1 master pre-screening trial and EVEREST-1 CAR T interventional trial.

Key Points: 
  • Additionally, A2 Bio is presenting two posters on November 4, 2023, detailing the BASECAMP-1 master pre-screening trial and EVEREST-1 CAR T interventional trial.
  • “BASECAMP-1 provides patients an early opportunity to be identified and triaged to the appropriate EVEREST logic-gate Tmod™ CAR T trial.
  • A2 Bio has partnered with Tempus, a leader in precision medicine, to bring the latest technology to patient screening.
  • Details of the presentations are below:
    The two posters will be available on the A2 Bio website after November 4, 2023.

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

Retrieved on: 
Lundi, août 28, 2023
Cancer, Therapy, Harbor, Lung cancer, Pharmacokinetics, HKEX, MSLN, Mab, Mesothelioma, ADC, Neoplasm, Ecosystem, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Breast cancer, Pharmaceutical industry

HBM9033 is an ADC drug candidate that specifically targets human mesothelin (MSLN), an upregulated tumor associated antigen in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers.

Key Points: 
  • HBM9033 is an ADC drug candidate that specifically targets human mesothelin (MSLN), an upregulated tumor associated antigen in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers.
  • HBM9033 utilizes a tumor specific cleavable linker with a novel topoisomerase inhibitor for improved stability and activity.
  • The unique design for both mAb and linker-payload together has demonstrated superior potency and safety of HBM9033 in pre-clinical studies.
  • This phase I study is to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM9033 in subjects with advanced solid tumors.